Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinued Operations (Details)

v3.19.2
Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinued Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jul. 15, 2019
Jul. 05, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jul. 17, 2018
Subsequent events | BioPharma Disposal              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gross consideration $ 23,500,000            
Closing adjustments 1,978,240            
Promissory note receivable 7,692,300            
Cash received from transaction $ 2,260,000            
Interest rate 6.00%            
Amount due if older accounts receivable are not collected prior to December 31, 2019 $ 830,000            
Convertible Note              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Term note, principal balance             $ 2,625,000
PFG | Secured Debt              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Term note, principal balance     $ 6,000,000.0   $ 6,000,000.0    
Maximum | Subsequent events | BioPharma Disposal              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Adjustment to net worth $ 775,000            
Clinical Agreement | Subsequent events              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Period of service   12 months          
Cash consideration received, total   $ 758,000          
Cash consideration received for equipment   45,000          
Advance from related party   1,000,000          
Supplier invoices paid directly to related party   177,000          
Transaction costs   $ 110,000          
Term of contract   24 months          
Non-compete term   3 years          
Transition Services Agreement | Maximum | Subsequent events | BioPharma Disposal              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Period of service 6 months            
Discontinued operations | Convertible Note              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Interest expense, debt     $ 657,000 $ 0 $ 1,442,000 $ 0